David Craig

CEO

David Craig is CEO of Sarcomatrix Therapeutics, a biotechnology company developing small molecule therapies for muscle diseases. He previously held executive roles at Amgen, Gilead and Alexion, and advocates for pragmatic, multi-modal innovation in rare disease drug development.

The concept of medical care for heart disease cardiac rhythm in the chart of tablets

Opinion

DMD Gene Therapy’s Inflection Point and the Case for Small Molecules

As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a deployable, scalable bridge, complementing genetic approaches and accelerating meaningful impact for patients with Duchenne muscular dystrophy.

September 4, 2025

6 min read

David Craig